Peer-reviewed veterinary case report
Bone marrow cell injection for injured knee ligament in dogs
By Linon, E et al.·Published in Veterinary journal (London, England : 1997)·2014·Vetsuisse Faculty Bern·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Engraftment of autologous bone marrow cells into the injured cranial cruciate ligament in dogs.
- Species:
- dog
Plain-English summary
An 8-year-old mixed-breed dog was treated for a torn cranial cruciate ligament (CCL) using its own bone marrow cells. The veterinarian injected these cells into the dog's knee joint to see if they would help heal the injury. After the treatment, some of the injected cells were found in the damaged ligament, indicating that they were able to settle there. The dog did not experience any complications during the year following the treatment, suggesting that this method could be a safe option for helping dogs with CCL injuries.
People also search for: dog CCL injury treatment · bone marrow cells for dog knee injury · torn ligament recovery in dogs
Abstract
Current research indicates that exogenous stem cells may accelerate reparative processes in joint disease but, no previous studies have evaluated whether bone marrow cells (BMCs) target the injured cranial cruciate ligament (CCL) in dogs. The objective of this study was to investigate engraftment of BMCs following intra-articular injection in dogs with spontaneous CCL injury. Autologous PKH26-labelled BMCs were injected into the stifle joint of eight client-owned dogs with CCL rupture. The effects of PKH26 staining on cell viability and PKH26 fluorescence intensity were analysed in vitro using a MTT assay and flow cytometry. Labelled BMCs in injured CCL tissue were identified using fluorescence microscopy of biopsies harvested 3 and 13 days after intra-articular BMC injection. The intensity of PKH26 fluorescence declines with cell division but was still detectable after 16 days. Labelling with PKH26 had no detectable effect on cell viability or proliferation. Only rare PKH26-positive cells were present in biopsies of the injured CCL in 3/7 dogs and in synovial fluid in 1/7 dogs. No differences in transforming growth factor-β1, and interleukin-6 before and after BMC treatment were found and no clinical complications were noted during a 1 year follow-up period. In conclusion, BMCs were shown to engraft to the injured CCL in dogs when injected into the articular cavity. Intra-articular application of PKH26-labelled cultured mesenchymal stem cells is likely to result in higher numbers of engrafted cells that can be tracked using this method in a clinical setting.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25261229/